Safety of vaccination against SARS-CoV-2 in people with rheumatic and musculoskeletal diseases: results from the EULAR Coronavirus Vaccine (COVAX) physician-reported registry

Annals of the Rheumatic Diseases, Год журнала: 2021, Номер 81(5), С. 695 - 709

Опубликована: Дек. 31, 2021

To describe the safety of vaccines against SARS-CoV-2 in people with inflammatory/autoimmune rheumatic and musculoskeletal disease (I-RMD).Physician-reported registry I-RMD non-inflammatory RMD (NI-RMDs) patients vaccinated SARS-CoV-2. From 5 February 2021 to 27 July 2021, we collected data on demographics, vaccination, diagnosis, activity, immunomodulatory/immunosuppressive treatments, flares, adverse events (AEs) breakthrough infections. Data were analysed descriptively.The study included 5121 participants from 30 countries, 90% I-RMDs (n=4604, 68% female, mean age 60.5 years) 10% NI-RMDs (n=517, 77% 71.4). Inflammatory joint diseases (58%), connective tissue (18%) vasculitis (12%) most frequent diagnostic groups; 54% received conventional synthetic disease-modifying antirheumatic drugs (DMARDs), 42% biological DMARDs 35% immunosuppressants. Most Pfizer/BioNTech vaccine (70%), 17% AstraZeneca/Oxford 8% Moderna. In fully cases, infections reported 0.7% 1.1% NI-RMD patients. flares 4.4% cases (0.6% severe), 1.5% resulting medication changes. AEs 37% (37% I-RMD, 40% NI-RMD), serious 0.5% (0.4% 1.9% NI-RMD).The profiles was reassuring comparable NI-RMDs. The majority tolerated their vaccination well rare reports flare very AEs. These findings should provide reassurance rheumatologists recipients promote confidence

Язык: Английский

---

Multimorbidity and adverse events of special interest associated with Covid-19 vaccines in Hong Kong

Nature Communications, Год журнала: 2022, Номер 13(1)

Опубликована: Янв. 20, 2022

Prior research using electronic health records for Covid-19 vaccine safety monitoring typically focuses on specific disease groups and excludes individuals with multimorbidity, defined as ≥2 chronic conditions. We examine the potential additional risk of adverse events 28 days after first dose CoronaVac or Comirnaty imposed by multimorbidity. Using a territory-wide public healthcare database population-based vaccination in Hong Kong, we analyze retrospective cohort patients Thirty special interest according to World Health Organization are examined. In total, 883,416 included 2,807 (0.3%) develop events. Results suggest vaccinated have lower risks than unvaccinated individuals, multimorbidity is associated increased regardless vaccination, association not modified To conclude, find no evidence that imposes extra following vaccination.

Язык: Английский

---

COVID-19 vaccines adverse events: potential molecular mechanisms

Immunologic Research, Год журнала: 2023, Номер 71(3), С. 356 - 372

Опубликована: Янв. 6, 2023

Язык: Английский

---

Reported COVID-19 vaccines side effects among Jordanian population: a cross sectional study

Human Vaccines & Immunotherapeutics, Год журнала: 2021, Номер 18(1)

Опубликована: Окт. 6, 2021

Concerns about the safety and side effects of coronavirus SARS CoV2 vaccines have been raised among many communities worldwide. The aim this study was to describe reported by vaccinated individuals in Jordan. A cross-sectional survey used recruit responses from participants who were with either one dose or both doses any administered Jordan (AstraZeneca, Pfizer, Sinopharm). total 1,086 enrolled study. Most not infected before receiving vaccine (77.2%). Larger proportion population received Pfizer (40.6%) followed AstraZeneca (33.0%), Sinopharm (26.4%). Side after first most (89.9%) included pain at injection site (78.4%), fatigue (51.8%), myalgia (37.6%), headache (33.1%), chills (32.3%). To a lesser extent, there gastrointestinal such as nausea (15.1%), loss appetite (9.4%), diarrhea (6.4%). More significantly associated (P < .001). Only case for each second that their required hospitalization. In study, we found people experienced more least is vaccine. Our showed these are severe should be an obstacle against successful control pandemic

Язык: Английский

---

Acceptance of a Third Dose of COVID-19 Vaccine and Associated Factors in China Based on Health Belief Model: A National Cross-Sectional Study

Vaccines, Год журнала: 2022, Номер 10(1), С. 89 - 89

Опубликована: Янв. 7, 2022

COVID-19 infections are returning to many countries because of the emergence variants or declining antibody levels provided by vaccines. An additional dose vaccination is recommended be a considerable supplementary intervention. We aim explore public acceptance third vaccine and related influencing factors in China. This nationwide cross-sectional study was conducted general population among 31 provinces November, 2021. collected information on basic characteristics, knowledge attitudes, vaccine-related health beliefs participants. Univariable multivariable logistic regression models were used assess associated with vaccine. A total 93.7% (95% CI: 92.9-94.6%) 3119 Chinese residents willing receive Individuals low level perceived susceptibility, benefit, cues action cues, high barriers, old age, educational level, monthly household income, score less likely have (all p < 0.05). In model, mainly previous history [Sinopharm BBIP (aOR = 6.55, 95% CI 3.30-12.98), Sinovac 5.22, CI:2.72-10.02), Convidecia 5.80, 2.04-16.48)], susceptibility 2.48, 1.48-4.31) 23.66, 9.97-56.23). Overall, China showed willingness accept vaccines, which can help manufacturers manage production distribution for huge domestic international demand. Relevant institutions could increase people's booster shots increasing initial rates, public's perception through various strategies channels. Meanwhile, it also has certain reference significance other formulate promotion strategies.

Язык: Английский

---

Prevalence of COVID-19 vaccines (Sputnik V, AZD-1222, and Covaxin) side effects among healthcare workers in Birjand city, Iran

International Immunopharmacology, Год журнала: 2021, Номер 101, С. 108351 - 108351

Опубликована: Ноя. 10, 2021

Язык: Английский

---

SARS-CoV-2 DNA Vaccine INO-4800 Induces Durable Immune Responses Capable of Being Boosted in a Phase 1 Open-Label Trial

The Journal of Infectious Diseases, Год журнала: 2022, Номер 225(11), С. 1923 - 1932

Опубликована: Янв. 24, 2022

Abstract Background Additional severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines that are safe and effective as primary boosters remain urgently needed to combat the disease 2019 (COVID-19) pandemic. We describe safety durability of immune responses following doses a homologous booster dose an investigational DNA vaccine (INO-4800) targeting full-length spike antigen. Methods Three dosage strengths INO-4800 (0.5 mg, 1.0 2.0 mg) were evaluated in 120 age-stratified healthy adults. Intradermal injection followed by electroporation at 0 4 weeks preceded optional 6–10.5 months after second dose. Results appeared well tolerated with no treatment-related serious adverse events. Most events mild did not increase frequency age subsequent dosing. A durable antibody response was observed 6 dose; significantly increased responses. Cytokine-producing T cells activated CD8+ lytic potential 2.0-mg group. Conclusions 2-dose series all adults, including elderly participants. These results support further development for use booster. Clinical Trials Registration NCT04336410.

Язык: Английский

---

Current advances and challenges in COVID-19 vaccine development: from conventional vaccines to next-generation vaccine platforms

Molecular Biology Reports, Год журнала: 2022, Номер 49(6), С. 4943 - 4957

Опубликована: Март 2, 2022

Язык: Английский

---

Oral lichen planus following the administration of vector‐based COVID‐19 vaccine (Ad26.COV2.S)

Oral Diseases, Год журнала: 2021, Номер 28(S2), С. 2595 - 2596

Опубликована: Сен. 20, 2021

All authors affirm that they have no conflict of interest. The peer review history for this article is available at https://publons.com/publon/10.1111/odi.14025.

Язык: Английский

---

COVID-19 Vaccines: Current and Future Perspectives

Vaccines, Год журнала: 2022, Номер 10(4), С. 608 - 608

Опубликована: Апрель 13, 2022

Currently available vaccines against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) are highly effective but not able to keep the coronavirus disease 2019 (COVID-19) pandemic completely under control. Alternative R&D strategies required induce a long-lasting immunological response and reduce adverse events as well favor rapid development large-scale production. Several technological platforms have been used develop COVID-19 vaccines, including inactivated viruses, recombinant proteins, DNA- RNA-based virus-vectored virus-like particles. In general, mRNA protein-based vectored shown high level of protection COVID-19. However, mutation-prone nature spike (S) protein affects vaccine its effectiveness, vaccinated people can become infected with new variants, also showing virus levels. addition, effects may occur, some them related interaction S angiotensin-converting enzyme 2 (ACE-2). Thus, there concerns that need be addressed challenges regarding logistic problems, such strict storage at low temperatures for vaccines. this review, we discuss limits developed possible innovative approaches.

Язык: Английский

---